M3 FY26 Net Profit Up 21% to ¥49.1bn as Revenue Accelerates +23% to ¥351bn; FY27 Guides Double-Digit Growth

M3, Inc. (TSE: 2413), the Tokyo-based healthcare-platform operator behind m3.com — Japan's dominant physician portal, with roughly 90% of the country's doctors registered — released its FY3/2026 consolidated earnings short report (Kessan Tanshin) under IFRS on May 1, 2026. Revenue rose 23.3% year-on-year to ¥351.4 billion (from ¥284.9 billion), operating profit rose 16.8% to ¥73.5 billion, pre-tax profit rose 17.7% to ¥76.3 billion, and profit attributable to owners of the parent rose 21.3% to ¥49.1 billion (from ¥40.5 billion). Basic EPS climbed to ¥72.53 from ¥59.62. The result marks a decisive re-acceleration after a softer FY25, with the top line growing more than 23% and margins recovering across the platform.

Revenue +23% and broad profit recovery

The headline story is the return of double-digit, in fact low-twenties, revenue growth. At ¥351.4 billion, the top line expanded by ¥66.5 billion in a single year, a pace M3 had not posted since its pandemic-era surge. Operating profit of ¥73.5 billion translates to an operating margin of 20.9% — down modestly from the prior year as the company reinvested in headcount and overseas expansion, but firmly back in M3's structural 20%-plus territory. Profit for the year (including minority interests) rose 21.9% to ¥54.0 billion, and the share attributable to owners of the parent rose 21.3% to ¥49.1 billion, with the gap reflecting M3's network of partly owned subsidiaries and joint ventures.

m3.com: the physician-platform engine

M3's economic moat is m3.com, the membership portal that connects pharmaceutical companies, medical-device makers and healthcare marketers to Japan's physicians. With roughly 90% of Japanese doctors registered, the platform is the default digital channel for medical information, detailing (online drug promotion), market research, and recruitment in Japan — a position that is extraordinarily difficult for a rival to replicate. This network effect underpins the high-margin Medical Platform segment and feeds adjacent businesses: as pharmaceutical marketing budgets continued to migrate from in-person sales reps to digital channels, M3's e-detailing and sponsored-content products captured an outsized share of that shift, driving the year's revenue re-acceleration.

Segment color: Medical Platform, Evidence, Career and overseas

M3 reports across several pillars built around the core physician network. The Medical Platform business — e-detailing, marketing support, and information services sold to pharma and device clients — remains the profit engine and the principal driver of the year's growth. Evidence Solutions spans clinical-trial support and contract-research (CRO) services, leveraging the doctor network for patient and investigator recruitment. Career Solutions covers physician and healthcare-professional recruitment and staffing, a structurally tight market in Japan. Site Solutions provides clinic and hospital IT and operational tools. Beyond Japan, M3's overseas operations — including platform and data businesses in the United States and Europe — add geographic diversification and were a meaningful contributor to the top-line acceleration as international medical-marketing and data demand recovered.

Cash flow strong, balance sheet at 64% equity

Operating cash flow rose to ¥70.3 billion from ¥51.7 billion, a sharp improvement that tracks the profit recovery and underscores the cash-generative, low-capital-intensity nature of a software-and-services platform. Total comprehensive income surged 63.5% to ¥68.2 billion, lifted by the profit gain together with favorable currency-translation movements on overseas subsidiaries. The balance sheet remains conservative: total assets stood at ¥637.4 billion and the equity ratio was 64.0%, leaving M3 with ample capacity to fund organic investment, bolt-on M&A, and continued shareholder returns without leverage strain.

Dividend lifted to ¥22; FY27 guides double-digit growth

For FY3/2026, M3 raised the year-end dividend to ¥22 per share (from ¥21), for a consolidated payout ratio of 30.3%. The FY3/2027 dividend is currently undecided, consistent with the company's practice of confirming the figure as the year progresses. For FY3/2027, M3 guides revenue of ¥400.0 billion (+13.8%), operating profit of ¥80.0 billion (+8.8%), pre-tax profit of ¥81.0 billion, and profit attributable to owners of ¥53.0 billion (+7.9%), with basic EPS of ¥78.29. The guidance signals continued double-digit revenue growth as the platform compounds, with profit growth running a step behind the top line as M3 keeps reinvesting in overseas expansion and product build-out.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.